matuzumab

Known as: humanized anti-EGFR monoclonal antibody 
A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity… (More)

Topic mentions per year

Topic mentions per year

2000-2018
051020002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers of various origins, and has… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
BACKGROUND Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2008
2008
An increasing number of therapeutic antibodies targeting tumors that express the epidermal growth factor receptor (EGFR) are in… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies… (More)
Is this relevant?
2008
2008
To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2007
2007
OBJECTIVE The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR… (More)
Is this relevant?
2006
2006
The humanised anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active against… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
BACKGROUND Epidermal growth factor receptor (EGFR) is overexpressed in 80%-90% of non-small-cell lung cancer (NSCLC). Matuzumab… (More)
Is this relevant?
2004
2004
  • Tracy E Kim
  • Current opinion in molecular therapeutics
  • 2004
Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a… (More)
Is this relevant?
2000
2000
Renal cell carcinoma (RCC) is a cytologically and histologically diverse disease in which a spectrum of distinct molecular… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?